In vitro activities of rifampin, colistin, sulbactam and tigecycline tested alone and in combination against extensively drug-resistant Acinetobacter baumannii

Journal of Antibiotics

Volumn 67, Issue 9, 2014, Pages 677-680

  Dong, Xiaomeng ^a   Chen, Fengzhe ^a   Zhang, Yajun ^a   Liu, Haihong ^a   Liu, Yongjuan ^a   Ma, Lixian ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIN; RIFAMPICIN; SULBACTAM; TIGECYCLINE; ANTIINFECTIVE AGENT; MINOCYCLINE;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIOSTASIS; BACTERIUM ISOLATION; BROTH DILUTION; CONTROLLED STUDY; DRUG POTENTIATION; EXTENSIVELY DRUG RESISTANT ACINETOBACTER BAUMANNII; FRACTIONAL INHIBITORY CONCENTRATION; HUMAN; IN VITRO STUDY; INHIBITORY CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; ACINETOBACTER INFECTIONS; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE;

ACINETOBACTER BAUMANNII;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; RIFAMPIN; SULBACTAM;

EID: 84921812281     PISSN: 00218820     EISSN: 18811469     Source Type: Journal    
DOI: 10.1038/ja.2014.99     Document Type: Article

References (17)

1. Playford, E. G., Craig, J. C. & Iredell, J. R. Carbapenem-resistant Acinetobacter baumannii in intensive care unit patients: Risk factors for acquisition, infection and consequences. J. Hosp. Infect. 65, 204-211 (2007).
2. Magiorakos, A.-P. et al. Multidrug-resistant, extensively drug-resistant and pandrugresistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 18, 268-281 (2012).
3. Corbella, X. et al. Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumannii. J. Clin. Microbiol. 38, 4086-4095 (2000).
4. Olson, M. W. et al. Functional, biophysical, and structural bases for antibacterial activity of tigecycline. Antimicrob. Agents. Chemother. 50, 2156-2166 (2006).
5. Chen, Q. et al. Decreased susceptibility to tigecycline in Acinetobacter baumannii mediated by a mutation in trm encoding SAM-dependent methyltransferase. J. Antimicrob. Chemother. 69, 72-76 (2014).
6. Simsek, F. et al. Colistin against colistin-only-susceptible Acinetobacter baumanniirelated infections: Monotherapy or combination therapy? Indian. J. Med. Microbiol. 30, 448-452 (2012).
7. Ji, J. et al. In vitro activity of sulbactam in combination with imipenem, meropenem, panipenem or cefoperazone against clinical isolates of Acinetobacter baumannii. Int. J. Antimicrob. Agents. 41, 400-401 (2013).
8. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twenty-first informational supplement (Document M100-S23CLSI, Wayne, PA, 2013).
9. Lee, K., Yong, D., Jeong, S. H. & Chong, Y. Multidrug-resistant Acinetobacter spp.: increasingly problematic nosocomial pathogens. Yonsei. Med. J. 52, 879-891 (2011).
10. Dijkshoorn, L, Nemec, A. & Seifert, H. An increasing threat in hospitals: multidrugresistant Acinetobacter baumannii. Nat. Rev. Microbiol. 5, 939-951 (2007).
11. Peleg, A. Y., Seifert, H. & Paterson, D. L. Acinetobacter baumannii: emergence of a successful pathogen. Clin. Microbiol. Rev. 21, 538-582 (2008).
12. Karah, N. et al. Emergence of OXA-carbapenemase- and 16S rRNA methylaseproducing international clones of Acinetobacter baumannii in Norway. J. Med. Microbiol. 60, 515-521 (2011).
13. Karah, N., Sundsfjord, A., Towner, K. & Samuelsen, O. Insights into the global molecular epidemiology of carbapenem non-susceptible clones of Acinetobacter baumannii. Drug Resist. Updat. 15, 237-247 (2012).
14. Stietz, M. S. et al. Acinetobacter baumannii extensively drug resistant lineages in Buenos Aires hospitals differ from the international clones I-III. Infect. Genet. Evol. 14, 294-301 (2013).
15. Martins, N. et al. Imported and intensive Care unit-born Acinetobacter baumannii clonal complexes: one-year prospective cohort study Q3 in intensive care patients. Microb. Drug Resist. 19, 216-223 (2013).
16. Farrell, D. J., Turnidge, J. D., Bell, J., Sader, H. S. & Jones, R. N. The in vitro evaluation of tigecycline tested against pathogens isolated in eight countries in the Asia-Western Pacific region (2008). J. Infect. 60, 440-451 (2010).
17. Shin, J. A. et al. Clinical Outcomes of Tigecycline in the Treatment of Multidrug-Resistant Acinetobacter baumannii Infection. Yonsei. Med. J. 53, 974-984 (2012).